Cardiovascular effects of selected water-miscible solvents for pharmaceutical injections and embolization materials: A comparative hemodynamic study using a sheep model

PDA Journal of Pharmaceutical Science and Technology

Volumn 61, Issue 2, 2007, Pages 64-74

  Laurent, Alexandre ^a,b   Mottu, Florence ^c   Chapot, René ^a   Jong, Qi Zhang ^a   Jordan, Olivier ^c   Rüfenacht, Daniel A ^c   Doelker, Eric ^c   Merland, Jean Jacques ^a,b  

^a HÔPITAL LARIBOISIÈRE   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Cardiovascular effects; Embolic liquids; Embolization; Hemodynamic toxicity; Interventional radiology; Intra arterial injection; Intravascular injection; Organic solvents; Parenteral route; Sheep model

Indexed keywords

1 METHYL 2 PYRROLIDINONE; 4 HYDROXYMETHYL 2,2 DIMETHYL 1,3 DIOXOLANE; ACETONE; ALCOHOL; DIGLYME; DIMETHYL ISOSORBIDE; DIMETHYL SULFOXIDE; GLYCEROL FORMAL; GLYCOFUROL 75; ISOSORBIDE; LACTIC ACID ETHYL ESTER; MACROGOL 200; ORGANIC SOLVENT; POLYMER; PROPYLENE GLYCOL; TETRAHYDROFURAN DERIVATIVE; TETRAHYDROFURFURYL ALCOHOL; UNCLASSIFIED DRUG;

ANEURYSM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTERIOVENOUS MALFORMATION; ARTERY CATHETERIZATION; ARTICLE; ARTIFICIAL EMBOLISM; CANCER THERAPY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG SOLUBILITY; HEART RATE; HEMODYNAMICS; INTERVENTIONAL RADIOLOGY; MALE; MISCIBILITY; NONHUMAN; SHEEP; TOXICITY TESTING; TUMOR; VENOUS PRESSURE;

ANIMALS; BLOOD PRESSURE; CHEMISTRY, PHARMACEUTICAL; EMBOLIZATION, THERAPEUTIC; HEART RATE; INFUSIONS, INTRA-ARTERIAL; MALE; MODELS, ANIMAL; PHARMACEUTICAL PREPARATIONS; POLYMERS; SHEEP; SOLUBILITY; SOLVENTS; TIME FACTORS; VENOUS PRESSURE; WATER;

EID: 34247530276     PISSN: 10797440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Kruss, B. Toxikologie and Verträglichkeit von Lösungsmitteln zur Parenteralen Anwendung. In Flüssige Arzneiformen Schwerlöslicher Arzneistoffe. Essig, S., Stumpf, H., Eds.; Wissenschaftliche Verlagsgesellschaft: Stuttgart, 1990, pp 42-61.
2. Füller, W. Vehikel und Hilfsmittel zur Herstellung von Injektionslösungen von Steroidhormonen. Pharm. Acta Helv. 1972, 47, 449-456.
3. Wells, J. I. Pharmaceutical Preformulation: The Physicochemical Properties of Drug Substances; Wiley; New York, 1988.
4. Wang, Y. C. J.; Kowal, R. R. Review of excipients and pH's for parenteral products used in the United States. J. Parent. Drug Assoc. 1990, 34, 452-462.
5. Spiegel, A. J.; Noseworthy, M. M. Use of non-aqueous solvents in parenteral products. J. Pharm. Sci. 1963, 52, 917-927.
6. Heintz, C.; Boymond, C. Aspects pharmacotoxicologiques et utilisation thérapeutique de quelques solvants injectables non aqueux miscibles à l'eau. STP Pharma 1989, 5, 548-560.
7. Nema, S.; Washkuhn, R. J.; Brendel, R. J. Excipients and their use in injectable products. PDA J. Pharm. Sci. Technol. 1997, 51 (4), 166-171.
8. Powell, M. F.; Nguyen, T.; Balvian, L. Compendium of excipients for parenteral formulations. PDA J. Pharm. Sci. Technol. 1998, 52 (5), 238-311.
9. Kruss, B. Die Hilfsstoffauswahl für Arzneiformen unter gesetzlichen und toxikologischen Aspekten. Acta Pharm. Technol. 1989, 35, 187-196.
10. Anschel, J. Lösungsmittel und Lösungsvermittler in Injektionen. Pharm. Ind. 1965, 27, 781-787.
11. Mandai, S.; Kinugasa, K.; Ohmoto, T. Direct thrombosis of aneurysms with cellulose acetate polymer. Part I. Results of thrombosis in experimental aneurysms. J. Neurosurg. 1992, 77, 497-500.
12. Kinugasa, K.; Mandai, S.; Terai, Y.; Kamata, I.; Sugiu, K.; Ohmoto, T.; Nishimoto, A. Direct thrombosis of aneurysms with cellulose acetate polymer. Part II. Preliminary clinical experience. J. Neurosurg. 1992, 77, 501-507.
13. Terada, T.; Nakamura, Y.; Nakai, K.; Tsuura, M.; Nishiguchi, M.; Hayashi, S., Kido, T.; Taki, W.; Iwata, H.; Komai, N. Embolization of arteriovenous malformations with peripheral aneurysms using ethylene vinyl alcohol copolymer. J. Neurosurg. 1991, 75, 655-660.
14. Matsumaru, Y.; Hyodo, A.; Nose, T.; Hirano, T.; Ohashi, S. Embolic materials for endovascular treatment of cerebral lesions. J. Biomater. Sci. Polymer Edn. 1997, 8, 555-569.
15. Mottu, F.; Gailloud, P.; Massuelle, D.; Rüfenacht, D. A.; Doelker, E. In vitro assessment of new embolic liquids prepared from preformed polymers and water-miscible solvents for aneurysm treatment. Biomaterials 2000, 21, 803-811.
16. Mottu, F.; Rüfenacht, D. A.; Laurent, A.; Doelker, E. Organic solvents for pharmaceutical parenterals and embolic liquids: A review of toxicity data. PDA J. Pharm. Sci. Technol. 2000, 54 (6), 456-469.
17. Chaloupka, J. C.; Gughelmi, G.; Vinuela, F. Direct thrombosis of aneurysms. J. Neurosurg. 1993, 78, 1006-1007.
18. Chaloupka, J. C.; Vinuela, F.; Vinters, H. V.; Robert, J. Technical feasibility and histopathologic studies of ethylene vinyl copolymer (EVAL) using a swine endovascular embolization model. Am. J. Neuroradiol. 1994, 15, 1107-1115.
19. Chaloupka, J. C.; Huddle, D. C.; Alderman, J.; Fink, S.; Hammond, R.; Vinters, H. V. A reexamination of the angiotoxicity of superselective injection of DMSO in the swine rete embolization model. Am. J. Neuroradiol. 1999, 20, 401-410.
20. Laurent, A.; Wassef, M.; Zhang, H. Q.; Brailliard, O.; Houdart, E.; Bailly, A. L.; Merland, J. J. Solutions gélifiantes pour embolisation: étude animale de la toxicité cardiovasculaire d'un constituant, le diméthylsulfoxyde. J. Neuroradiol. 1997, 24, 314.
21. Mottu, F.; Stelling, M.-J.; Rüfenacht, D. A.; Doelker, E. Comparative haemolytic activity of undiluted organic water-miscible solvents for intravenous and intra-arterial injection. PDA J. Pharm. Sci. Technol. 2001, 55 (1), 16-23.
22. Dudeck, O.; Jordan, O.; Hoffmann, K. T.; Tesmer, K.; Kreuzer-Nagy, T.; Okuducu, A. F.; Rüfenacht, D. A.; Felix, R.; Doelker, E. Angiotoxicity studies of organic solvents as more compatible vehicles for precipitating liquid embolics: A comparative study with superselective injections of swine rete mirabile. AJNR Am. J. Neuroradiol. 2006, 27, 1900-1906.
23. Food and Drug Administration (FDA). Bioequivalence guidance, U.S. Department of Health and Human Services, October 2002.
24. Westlake, W. W. Bioavailability and bioequivalence of pharmaceutical formulations. In Biopharmaceutical Statistics for Drug Development, Peace, K., Ed.; Marcel Dekker New York, 1988; pp 329-352.
25. Schuirmann, D. J. A Comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J. Pharm. Biopharm. 1987, 15, 657-680.
26. Camp, P. E.; James, H. E.; Werner, R. Acute diethyl sulfoxide therapy experimental brain edema: Part 1. Effects on intracranial pressure, blood pressure, central venous pressure, and brain water and electrolyte content. Neurosurgery 1981, 9, 28-33.
27. Kassel, N. F.; Sprowell J. A.; Boarini, D. J.; Olin, J. J. Effect of dimethyl sulfoxide on the cerebral and systemic circulations of the dog. Neurosurgery 1983, 12, 24-28.
28. Shimizu, S.; Simon, R. P.; Graham, S. H. Dimethylsulfoxide (DMSO) treatment reduces infarction volume after permanent focal cerebral ischemia in rats. Neuroscience Letters 1997, 239, 125-127.
29. Marshall, L. F.; Camp, P. E.; Bowers, S. A. Dimethyl sulfoxide for the treatment of intracranial hypertension: A preliminary trial. Neurosurgery 1984, 14, 659-663.
30. Levett, J. M.; Johns, L. M.; Grina, N. M.; Mullan, B. F.; Kramer, J. F.; Mullan, J. F. Effects of dimethyl sulfoxide on systemic and cerebral hemodynamic variables in the ischemic canine myocardium. Crit. Care Med. 1987, 15, 656-660.
31. Brown, F. D.; Jones, L. M.; Mullan, S. Dimethyl sulfoxide in experimental brain injury, with comparison to mannitol. J. Neurosurg. 1980, 53, 58-62.
32. Kramer, K.; van Acker, S. A. B. E.; Grimbergen, J. A.; van den Berg, D.-J.; van der Vijgh, W. J. F.; Bast, A. Effect of dimethyl sulfoxide (DMSO) on the electrocardiogram (ECG) in freely moving male balb/c mice. Gen. Pharmac. 1995, 26, 1403-1407.
33. Budden, R.; Kühl, U. G.; Buschmann, G. Ausgewählte Untersuchungen zur pharmakodynamischen Eigenwirkung verschiedener Lösungsvermittler. 1. Mitteilung: Äthyldiäthylenglykol, N,N-Diäthyllactamid, Dimethysulfoxid. Arzneim.-Forsch./Drug Res. 1978, 28, 1571-1579.
34. Bazil, M. K.; Krulan, C.; Webb, R. L. Telemetric monitoring of cardiovascular parameters in conscious spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 1993, 22, 897-905.
35. Domer, F. R. Cardiovascular and neuromuscular effects of dimethylsulfoxide in anaesthetized rabbits. J. Pharm. Sci. 1977, 66, 269-270.
36. DiStefano, V.; Klahn, J. J. Observations on the pharmacology and hemolytic activity of dimethyl sulfoxide. Toxicol. Appl. Pharmacol. 1965, 7, 660-666.
37. Varma, R. K.; Kausha, R.; Thomas, G. P.; Junnarkar A. V.; Singh, P. P.; Tripathi, R. M. Evaluation of dimethyl sulfoxide as a solvent in pharmacological experiments. Ind. J. Exp. Biol. 1987, 25, 758-760.
38. Peterson, C. G.; Robertson, R. D. A pharmacodynamic study of dimethyl sulfoxide. Ann. N.Y. Acad. Sci. 1967, 141, 273-276.
39. De La Torre, J. C.; Rowed, D. W.; Kawanaga, H. M.; Mullan, S. Dimethyl sulfoxide in the treatment of experimental brain compression. J. Neurosug. 1973, 38, 345-354.
40. Hameroff, S. R.; Otto, C. W.; Kanel, J.; Weinstein, P .R.; Blitt, C. D. Acute cardiovascular effects of dimethyl sufoxide. Ann. N.Y. Acad. Sci. 1983, 411, 94-99.
41. Yakes, W. F.; Baker, R. Cardiopulmonary collapse: Sequelae of ethanol embolotherapy. Radiology 1993, 189, 145.
42. Mitchell, S. E.; Shah, A. M.; Schwengel, D. Pulmonary artery pressure changes during ethanol embolization procedures to treat vascular malformations: can cardiovascular collapse be predicted? J. Vasc. Interv. Radiology 2006, 17, 253-262.
43. Mason, K. P.; Michna, E.; Zurakowsky, D.; Koka, B. V.; Burrows, P. E. Serum ethanol levels in children and adults after ethanol embolization or sclerotherapy for vascular anomalies. Radiology 2000, 217, 127-132.
44. Anadon, M. J.; Almendral, J.; Gonzalez, P.; Zaballos, M.; Delcan, J. L.; De Guevara, J. L. Alcohol concentration determines the type of atrial arrhythmia induced in a porcine model of acute alcoholic intoxication. Pacing Clin. Electrophysiol. 1996, 19 (11), 1962-1967.
45. Kusano, S.; Ohta, A. A complication and hazard of transcatheter obliteration of the renal artery with absolute ethanol in dogs. Invest. Radiol. 1985, 20, 36-41.
46. Hammer, F. D.; Boon, L. M.; Mathurin, P.; Vanwijck, R. R. Ethanol sclerotherapy of venous malformations: Evaluation of systemic ethanol contamination. J. Vasc. Interv. Radiol. 2001, 12, 595-600.
47. Lee, J. J.; Do, Y. S.; Kim, J. A. Serum ethanol levels after alcohol sclerotherapy of arteriovenous malformations. J. Korean Med. Sci. 2004, 19, 51-54.
48. Yakes, W.; Rossi, P.; Odink, H. Arteriovenous malformation management. Cardiovasc. Interv. Radiol. 1996, 19, 65-71.
49. Shin, B. S.; Do, Y. S.; Lee, B. B.; Kim, D. I.; Chung, I. S.; Cho, H. S.; Kim, M. H; Kim, G. S.; Kim, C. S.; Byun, H. S.; Shin, S. W.; Park, K. B. Multistage ethanol sclerotherapy of soft-tissue arteriovenous malformations: Effect on pulmonary arterial pressure. Radiology 2005, 235, 1072-1077.
50. Do, Y. S.; Yakes, W. F.; Shin, S. W.; Lee, B. B.; Kim, D. I.; Liu, W. C.; Shin, B. S.; Kim, D. K.; Choo, S. W.; Choo, I. W. Ethanol embolization of arteriovenous malformations: Interim results. Radiology 2005, 235, 674-682.
51. Budden, R.; Kühl, U. G.; Buschmann, G. Ausgewählte Untersuchungen zur pharmakodynamischen Eigenwirkung verschiedener Lösungsvermittler. 3. Mitteilung: (1,2)-Propandiol, Tetrahydrofurfurylalkohol-poly!äthylenglycoläther (THFP), Polyoxy!athylensorbitanmonooleat (PSM). Arzneim.-Forsch./Drug Res. 1978, 28, 1586-1593.
52. Budden, R.; Kühl, U. G.; Buschmann, G. Ausgewählte Untersuchungen zur pharmakodynamischen Eigenwirkung verschiedener Lösungsvermittler. 2. Mitteilung: Glycerin, N-Hydroxy!äthyllactamid, Poly!äthylenglycol 400. Arzneim.-Forsch./Drug Res. 1978, 28, 1579-1586.
53. Heilman, R. D.; Bauer, E. W.; DaVanzo, J. P. Effect of polyethylene glycol on the cardiovascular response of the dog autonomic agents. Toxicol. Appl. Pharmacol. 1972, 23, 263-270.
54. Browning, E. Toxicity and Metabolism of Industrial Solvents; Elsevier S: Amsterdam, 1965.
55. Cheav, S. L.; Salloum, S.; Pieri, F.; Kirkiacharian, S. Action du glycérolformal sur le système cardiovasculaire, Ann. Pharm. Fr. 1985, 43, 491-503.
56. Bost, J.; Ruckebusch, Y. Toxicité et pharmacologie du propyléne-glycol. Thérapie 1962, XVII, 83-94.